|
|
Effect of the combination of pegylated liposomal doxorubicin and bortezomib on time to progression (TTP) and overall survival of patients with relapsed/refractory multiple myeloma compared with bortezomib alone.
|
|
|
06.10.07 |
Jean Luc Harousseau, MD
CHU Hotel Dieu
Nantes, France
|
 related articles
|
|
back
print